Study: Novo Nordisk NN9489-8033 “AMBITION 1”

Are you living with type 2 diabetes and managing your diabetes with diet and exercise only (no diabetes medications)?

If so, you may be eligible to participate in a clinical research study assessing an investigational GLP-1 medicine called zenagamtide.

ABOUT THE STUDY

This is a Phase 3 study assessing how zenagamtide affects blood sugar levels and body weight.

Who may qualify?

You may be eligible to participate if you meet all the following:

• Age 18 years or older

  Have type 2 diabetes

  Have never taken any glucose-lowering medications (your diabetes has always been treated with diet and exercise only)

  HbA1c between 7.0% and 9.5%

  BMI of 23 or higher (classified as normal weight, overweight, or obesity)

  Have never used any GLP-1-based medication — pills or injections (such as Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, or Foundayo), for any reason

  Have never had surgery for treatment of obesity

Interested in learning more?
Click below to complete a short questionnaire to see if you may be eligible.
(insert JotForm link)